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Abstract
Background: The ARE insertion/deletion polymorphism of PPP1R3A has been associated with
variation in glycaemic parameters and prevalence of diabetes. We have investigated its role in age
of diagnosis, body weight and glycaemic control in 1,950 individuals with type 2 diabetes in Tayside,
Scotland, and compared the ARE2 allele frequencies with 1,014 local schoolchildren.
Results: Men homozygous for the rarer allele (ARE2) were younger at diagnosis than ARE1
homozygotes (p = 0.008). Conversely, women ARE2 homozygotes were diagnosed later than ARE1
homozygotes (p = 0.036). Thus, men possessing the rarer (ARE2) allele were diagnosed with type
2 diabetes earlier than women (p < 0.000001). In contrast, there was no difference in age of
diagnosis by gender in those individuals carrying only the common ARE1 variant. Furthermore,
although there was no difference in the frequency between the children and the type 2 diabetic
population overall, marked differences in allele frequencies were noted by gender and age-of
diagnosis. The ARE2 allele frequency in early diagnosed males (diagnosed earlier than the first
quartile of the overall ages at diagnosis) was higher than that found in both later diagnosed males
and healthy children (p = 0.021 and p = 0.03 respectively). By contrast, the frequency in early
diagnosed females was significantly lower than later diagnosed females and that found in children
(p = 0.021 and p = 0.037).
Comparison of the male to female ratios at different ages-diagnosed confirms a known
phenomenon that men are much more prone to early type 2 diabetes than women. When this
feature was examined by the common ARE 1/1 genotype we found that the male to female ratio
remained at unity with all ages of diagnosis, however, carriers of the ARE2 variant displayed a
marked preponderance of early male diagnosis (p = 0.003).
Conclusion: The ARE2 allele of PPP1R3A is associated with a male preponderance to early
diagnosed type 2 diabetes. Susceptibility to type 2 diabetes in later life is not modulated by the
ARE2 allele in either sex.
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Background
Subgroups of patients with type 2 diabetes mellitus or fea-
tures of the metabolic syndrome have been shown to have
impaired insulin-dependent whole body glucose uptake
[1], the principal component of which is non-oxidative
glycogen synthesis in skeletal muscle [2]. Glycogen-syn-
thase (GS) catalyses one of the rate-determining steps in
glycogen synthesis in muscle and defective insulin-medi-
ated activation of muscle GS has been found in glucose
tolerant, but insulin resistant first-degree relatives of Cau-
casian type 2 diabetic patients [3]. GS is activated in
response to insulin through its net dephosphorylation
mediated by inhibition of kinases such as glycogen syn-
thase kinase-3 and activation of glycogen-bound protein
phosphatase-1 enzyme in response to insulin [4]. In insu-
lin-resistant Pima Indians decreased activities of both GS
and glycogen-associated protein phosphatase-1 in muscle
tissue has been demonstrated [5,6] providing a mecha-
nism by which GS activation by insulin is reduced in these
subjects.
The most abundant glycogen-associated protein phos-
phatase-1 (PP-1) derived from skeletal muscle is a het-
erodimer composed of a 37 kDa ubiquitous catalytic
subunit and a 160 kDa glycogen-targeting and regulatory
subunit, GM[7]. PP1GM has been shown to play an impor-
tant role in the regulation of glycogen synthase activity [8]
and may participate in the insulin stimulation of glycogen
synthesis [9]. The gene encoding GM(PPP1R3A) has been
located on chromosome 7 [10] in a region in which
genome wide scanning in Pima Indians has found mark-
ers linked to quantitative traits related to glucose metabo-
lism. Recently a rare premature stop mutation has been
detected which produced severe familial insulin resistance
when occurring with an unlinked frame shift mutation in
a further candidate gene, PPARG. [11]. This digenic inher-
itance serves as a paradigm for the interaction of variation
at diverse locations in the genome contributing to the
development of the insulin resistant phenotype. Several
common variants of PPP1R3A  have also been variably
associated with features of insulin resistance and type 2
diabetes in different populations [10,12–17]. In particular
a 5 bp length insertion deletion polymorphism in the 3'-
untranslated region (UTR) of the gene gives rise to a dif-
ference in distance between two AT rich elements (ARE),
which have been implicated in mRNA stability [18,19]
The deletion variant (allele ARE2) has been found to
decrease mRNA half life, and PPP1R3A transcript and pro-
tein concentrations in vivo [10] and displays increased
binding of a protein responsible for the increased turno-
ver [20]. Thus, the ARE2 variant has implications for the
extent of activation of muscle GS by insulin and hence
overall insulin sensitivity. This has recently been con-
firmed by the deletion of the gene for PPP1R3A in mice
which results in a markedly insulin resistant phenotype.
[21].
The ARE2 allele frequency has been reported to be higher
in young type 2 diabetics than a control population in
Japan [12] and higher in early diagnosed than late diag-
nosed type 2 diabetic Pima Indians [10]. In another study
ARE2 was weakly associated with whole body insulin sen-
sitivity, with the allele being associated with a trend of
higher fasting insulin levels and lower insulin mediated
glucose uptake [15]. In contrast a study of aboriginal
Canadians showed that ARE2 homozygotes had a lower 2
hour post challenge plasma glucose in type 2 diabetics
and individuals with impaired glucose tolerance [14].
Thus the role of the PPP1R3A ARE polymorphism in the
susceptibility to type 2 diabetes is not clear.
As previous studies have demonstrated an association of
the ARE2 variant of PPP1R3A with early diagnosed type 2
diabetes and other glycaemic parameters, we have exam-
ined its role in such parameters in a genetic sub-study of
the Diabetes Audit and Research in Tayside Scotland
(DARTS) [22]. In addition we have used a population of
local children (aged 5–8) to determine the local gene fre-
quency of the ARE variants at birth, and have examined
the divergence from this baseline frequency within the
type 2 diabetic population.
Results
We have determined the frequency of the PPP1R3A ARE
polymorphism in a large group (n = 1950) of approxi-
mately equal numbers of men and women with type 2
diabetes in Tayside, Scotland and considered association
of genotype with age of diagnosis with type 2 diabetes,
glycated haemoglobin and body mass index. 847 (43.4%)
were ARE1 homozygotes, 891 (45.7%) ARE1/2 heterozy-
gotes and 212 (10.9%) ARE2 homozygotes. Overall the
ARE2 allele frequency was 0.337 (0.322–0.352). ARE gen-
otype demonstrated a strong association with age of diag-
nosis that was both gene dosage and gender dependent
(Table 1 and Figure 1). Thus whilst there was no difference
between males and females in the mean age of diagnosis
for individuals homozygous for the more common ARE1
allele (56.5 years vs 56.7 years respectively), males
carrying the less common ARE2 allele (heterozygotes and
ARE2 homozygotes) had an earlier mean age of diagnosis
(55.1 years) compared with females carrying the ARE2
allele (58.6 years) a difference of 3.6 years which was
highly significant (p < 0.000001). Furthermore female
ARE2 carriers were on average 2 years older (p = 0.017) at
diagnosis than female ARE1 homozygotes. On the other
hand male ARE2 carriers were 1.5 years younger (p =
0.046) at diagnosis compared to male ARE1 homozy-
gotes. Thus males and females who had the ARE2/2 geno-
type differed in mean age of diagnosis by on average 6.5BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/11
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years (3.1–9.5, p = 0.0001). Over all there was also a weak
association of the rare allele with body mass index after
adjustment for age of diagnosis, age of BMI, and treat-
ment, with homozygous ARE2 individuals having a BMI
0.81 lower than ARE1 homozygous individuals (p =
0.041). This association was however confined to females
(BMI difference = 1.41, p = 0.021) with males showing no
evidence of a difference (p = 0.939). There was also a weak
association with glycated haemoglobin in the overall pop-
ulation and again this association was confined to females
ARE2 homozygotes who had a glycated haemoglobin on
average 1% lower than ARE1 homozygotes (p = 0.047).
As we found an association of reduced BMI with genotype
in females, and increased BMI is known to be the major
risk for type 2 diabetes, we included BMI in our regression
model for age of diagnosis. This completely removed any
significance in the association (Table 1). Interestingly,
inclusion of BMI in the regression model in men did not
negate the association with earlier age of diagnosis.
To further explore the association of this polymorphism
with gender and age of diagnosis, we compared allele fre-
quencies by gender in individuals diagnosed early and
those diagnosed later. Early and later diagnosis were
defined as being diagnosed at an age below and above the
first quartile of the overall ages at diagnosis respectively.
This corresponded to being diagnosed less than or greater
than 48.2 years in this population. These frequencies were
in turn compared with the background population fre-
quency in a large cohort (495 males, 519 females) of
healthy school children from the same region. The overall
ARE2 allele frequency in the children was very close to the
overall frequency in the diabetic population (Table 2 and
figure 2). There was no difference in allele frequency
between genders in the children (ARE1 allele frequency in
males = 0.336, 0.307–0.366 vs. females 0.330, 0.302–
0.359). As expected while there was no difference in ARE2
allele frequency between males and females diagnosed
later (OR 0.927, 0.793–1.084 p = 0.333) the frequency in
early diagnosed males and females was significantly dif-
ferent (OR 1.59, 1.20–2.12 p = 0.0009). The frequency in
males was 0.383 (0.342 – 0.423) which was significantly
higher (OR 1.24, 1.015–1.51, p = 0.030) than the back-
ground frequency in the children and in early diagnosed
females it was 0.280 (0.237 – 0.324) which was in turn
significantly lower (OR 0.78, 0.611–0.991, p = 0.037)
than the background frequency in the children. The fre-
quency in the women diagnosed early was also signifi-
cantly lower than the frequency in those diagnosed later
(OR 0.740, 0.576–0.947, p = 0.014). These frequencies
were also similarly different in male type 2 diabetics (OR
1.269, 1.030–1.561 p = 0.021).
Finally, analysis of the ratio of males to females in the
total DARTS population and the genetic sub-study (Go-
DARTS) showed a marked overall preponderance of early
diagnosis for males that is very similar to that observed in
previous epidemiological studies (figure 3a). This was
supported by a χ2, test for trend, of 129.9, p < 0.0001, for
the total DARTS population and a χ2 test for trend of 17.9,
p < 0.0001, in the genotyped subpopulation. This trend
resided exclusively in the ARE2 allele carriers with no such
trend in ARE1 homozygotes (p = 0.003 for comparison of
trends by genotype) (figure 3b).
Discussion
We have demonstrated that the ARE polymorphism of
PPP1R3A is associated with age of diagnosis in the Tayside
type 2 diabetic population and that this association is
Table 1: Characteristics of the Tayside Diabetic population by PPP1R3A genotype and sex. Parameters are given as corrected means 
± Standard deviation, the corrected means are based on multiple measures through time and are adjusted for age diagnosed, age at 
which parameter was measured and drug treatment at time of measurement.
Male ARE1/1 ARE1/2 ARE2/2 p value
N 432 479 111
Age Diagnosed (years) 56.5 ± 0.6 55.5 ± 0.5 †53.2 ± 1.1 0.008 (0.011*)
BMI (Kg/m2) 29.9 ± 0.2 29.7 ± 0.2 29.9 ± 0.5 NS
GHB (%) 7.6 ± 0.05 7.5 ± 0.05 7.5 ± 0.1 NS
Female ARE1/1 ARE1/2 ARE2/2 p value
N 415 412 101
Age Diagnosed (years) 56.7 ± 0.6 58.4 ± 0.6 †59.5 ± 1.2 0.038 (0.2*)
BMI (Kg/m2) 31.6 ± 0.3 31.2 ± 0.3 30.3 ± 0.6 0.021
GHB (%) 7.8 ± 0.05 7.7 ± 0.05 7.5 ± 0.1 0.047
* = p value after inclusion of BMI-at-diagnosis in the linear regression model. †p = 0.0001 for comparison between male and female ARE2 homozy-
gotes (recessive model) p < 0.000001 for a comparison between male and female allele carriers (co-dominant model).BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/11
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both gender and gene dosage dependent. We know from
the United Kingdom Prospective Diabetes Study popula-
tion that there is a preponderance of males at younger
ages of diagnosis and that the proportion of men to
women decreased at higher ages of diagnosis [23]. We
have reproduced this observation in the DARTS popula-
tion, however this appears to be confined to ARE2 carriers
with no such trend being observed in the ARE1 homozy-
gotes. We have also found a weak association of ARE gen-
otype with BMI and glycated haemoglobin which again
appears gender dependent with the association being
found exclusively in females. Inclusion of BMI in the
model for age of diagnosis attenuated its association with
genotype in the females which suggests that the ARE2 var-
iant is associated with a protection from obesity-induced
diabetes in women. The lack of an attenuation in males
indicates that the ARE2 allele may predispose men to type
2 diabetes, in a manner independent of obesity.
The overall frequency of the ARE2 variant obtained in the
adult population of individuals with type 2 diabetes is
almost identical to the frequency found in the children
from the same geographical region and these are similar
to other published frequencies in Japanese [12], Cauca-
sian [15] and aboriginal Canadian [14] populations. In
the study from the Pima Indians however the frequency
was found to be considerably higher [10]. In the Japanese
population the mean age of diagnosis was similar to the
youngest quartile in our population. Examination of the
allele frequencies in the men and women diabetics in this
population compared with the control population reveals
that the risk of diabetes attributable to the variant was pre-
dominantly in the males (0.347 vs. 0.288, p = 0.03) and
was less evident in the females (0.326 vs. 0.288, p = 0.19)
[12]. This young-diagnosed population also had a male
preponderance similar to that observed in our study. The
Pima Indian study which examined the relative risk of
diagnosis with type 2 diabetes diagnosis before and after
the age of 45 also found a significant predominance of the
ARE2 variant in the younger age group [10]. In contrast to
our study, and that of the Japanese group, this population
had a strong female preponderance. Indeed, it is clear that
female Pima Indians are not afforded the protection from
early type 2 diabetes that is observed in Caucasian popu-
lations, and this is likely to be due to the extremely high
prevalence of morbid obesity in these women.
There has only been one published study of any signifi-
cant size that fails to support the involvement of the ARE
polymorphism in type 2 diabetes susceptibility. This
study is a prospective study of 696 Swedish men that have
been followed for 20 years [15]. Although significant
effects of the ARE polymorphism on insulin sensitivity
were observed, there was no effect of the ARE polymor-
phism on incident diagnoses of type 2 diabetes. However,
this study recruited at age 50 years, and excluded any indi-
viduals with a diagnosis of type 2 diabetes or showed evi-
dence of abnormal glucose homeostasis. This means that
the prospective Swedish study excluded exactly the popu-
lation which demonstrated ARE-related risk, both in our
study and in the previous Japanese and Pima studies.
Indeed, as our study is an unselected population cohort
we reconcile the negative results obtained in the Swedish
study, in that the ARE polymorphism is not significantly
associated with type 2 diabetes risk in the over 50 s. These
results are summarised in table 3 and illustrate how differ-
ent mixes of sex and age at diagnosis in different case-con-
>Age diagnosed with type 2 diabetes in males and females by  PPP1R3A ARE genotype Figure 1
Age diagnosed with type 2 diabetes in males and 
females by PPP1R3A ARE genotype. Legend: Females 
dashed line open triangle, males solid line closed squares. 
(Error bars = standard error of the mean)
Odds ratios of the ARE2/2 genotype prevalence in type 2  diabetes Figure 2
Odds ratios of the ARE2/2 genotype prevalence in 
type 2 diabetes. Shown are the Odds Ratios and the 95% 
confidence intervals.BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/11
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trol studies may modulate observed associations with
ARE2 and susceptibility to type 2 diabetes.
It is not possible from the present study to determine the
physiological basis of the differences in males and females
observed by PPP1R3A genotype although it is probable
that the differing hormonal environments in pre-meno-
pausal females is a contributing factor. The mean age of
menopause in Caucasian women is 50.5 years and the fre-
quency of the ARE2 allele in women was found to rise
steadily to about this age after which it plateaus [data not
shown] to a similar level to that found in the children. It
is known that women generally have improved glucose
tolerance and increased skeletal muscle sensitivity com-
pared to men [24–26] Recently it has been demonstrated
in both rats and humans that lipid infusions lead to insu-
lin resistance in males but not in females. [27,28] It could
be speculated that this variant of the PPP1R3A gene plays
a role in determining response to the high dietary fat
intake in the east of Scotland differentially between males
and females although the mechanism for this is obscure at
present.
Conclusions
The ARE polymorphism has been associated with suscep-
tibility to type 2 diabetes in several case-control studies.
We have shown for the first time using a population-based
cohort of unselected individuals with type 2 diabetes that
the ARE2 allele is associated with gender selective modu-
lation of the age of diagnosis of type 2 diabetes. This work
supports the initial findings that the ARE2 variant modu-
lates susceptibility to type 2 diabetes and indicates an ave-
nue of further investigation for determining physiological
basis of gender specific differences in peripheral insulin
resistance and onset of type 2 diabetes.
Methods
Tayside Type 2 Diabetic Population
In Tayside, Scotland detailed clinical information on all
individuals with diabetes mellitus is recorded on an elec-
tronic clinical information system known as DARTS (Dia-
betes Audit and Research in Tayside Scotland) which has
been described elsewhere [22]. In brief, electronic record
linkage techniques have identified all people with diabe-
tes in the population of Tayside with a sensitivity of 97%.
All clinical data are recorded according to a standard data-
set and all case records are validated by a team of dedi-
cated research nurses who create a "cradle to the grave"
electronic record. Thus age of diagnosis is rigorously
retrospectively determined to coincide with age of onset.
All such patients are randomly invited to participate in a
genotyping initiative. Following written informed con-
sent, a single sample of blood is collected for DNA extrac-
tion and genotyping and the individual assigned a unique
system code number for anonymisation purposes. Full
compliance with NHS data protection and encryption
Table 2: Genotype and ARE2 allele frequency (with 95% confidence intervals) in men and women diagnosed with early and late diagnosis 
of type 2 diabetes.
Males Females Children
Early Late Early Late
ARE11 106 326 104 311 457
ARE12 130 349 87 325 438
ARE22 41 70 14 87 119
Total 277 745 205 723 1014
ARE2 frequency 0.383(0.342–0.423) 0.328(0.304–0.352) 0.280(0.237–0.324) 0.345(0.321–0.370) 0.333(0.313–0.354)
Table 3: Concordant relationships between this and previous studies regarding ARE variants and type 2 diabetes
Age at diagnosis Study Sample size (n) Ethnicity Sex imbalance Association of ARE variants with diabetes
Younger Maegawa et al [12] 426 Japanese Yes Yes
Xia et al [10] 930 Pima Yes Yes
This study 482 Caucasian Yes Yes
Later Hansen et al [15] 696 Caucasian Yes No
This study 1,468 Caucasian No No
All studies with >200 diabetic individuals are included, 2 studies were excluded due to small sample size and lack of information regarding age of 
diagnosis [14,29]. Both of these studies did present significant associations with either disease susceptibility or insulin homeostasis.BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/11
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standards is maintained. Genotype information is stored
together with the anonymised clinical information on an
SQL database. The population in this study therefore con-
sisted of a free-living clinical population selected only on
the basis of having type 2 diabetes and attending a diabe-
tes clinic in Tayside. All subjects were of Caucasian ethnic-
ity. All recorded measures of BMI and percentage glycated
haemoglobin together with age at diagnosis for each indi-
vidual was extracted from the DARTS database.
Tayside Children Population
Healthy school children recruited for a gene/nutrition
interaction study in the Tayside region of Scotland were
used as a control population in this study. They were
>95% Caucasian and selected at random from local pri-
mary schools. Following informed parental consent
mouthwash samples were collected for DNA analysis.
DNA analysis
PPP1R3A  ARE polymorphism was analysed using
TaqMan-based allelic discrimination assays on a Applied
Biosystems 7700 Sequence Detection System. The
oligonucleotides used for this assay were:
Primer 1; CAGATAAAACATGGACAATGGCAG.
Primer 2; GGTTGAAATATTTGATCAATGAATCCTG.
ARE1 PROBE (FAM/TAMRA Labelled):
TGGTCTTTTAGTATTGAACATGAAATTTGTATTTAACACT
GTATC.
ARE2 PROBE (TET/TAMRA Labelled)
;TGGTCTTTTAGTATTGAACATGAAATTTGTTCAATTTATC
ATTTA
Assays were performed using reagents and conditions as
supplied by the manufacturer (Applied Biosystems, Foster
City, CA)
Statistics
Allele frequencies were compared using Pearsons's Chi
Square. Linear regression was used to assess the affect of
genotype on Age of Diagnosis. Repeated measures of Body
Mass Index and Glycated haemoglobin were used in a
repeated measures model which included age diagnosed,
age at which parameter was measured and a term for
whether the parameter was measured while the individual
was on or off drug therapy for type 2 diabetes including
insulin. These parameters were normalised by Log10
transformation. All statistical analyses were performed
using algorithms available in turbocharged STATA v7. For
consideration of gene frequencies by age diagnosed the
population was analysed by quartiles and early diagnosis
was classified as being within the first quartile of age diag-
nosed. Chi squared test for trend was used to examine the
gender ratios by quintile and logistic regression analysis
was used to compare relative frequencies of the females to
males over the quintiles by genotype. All ranges stated in
the text are 95% confidence intervals.
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